Australian radiopharmaceutical company Advancell Co. Ltd. closed an AU$18 million (US$12.4 million) series B round that will take its lead targeted alpha-emitting radiotherapy, ADVC-001, for metastatic prostate cancer to the clinic by the end of 2022.

Cell Envision Ltd. completed an angel round that will help expand its presence in the U.S. and Europe. Taiwan-based Cell Envision has developed a self-assembled cell arrangement (SACA) monitoring system that can improve patient survival rates of cancer, together with enhancements in reproductive medicine.

Xeltis BV raised $15 million in series D2 funding to develop its restorative vascular access device for patients with chronic kidney disease who are on hemodialysis. The investment in this technology, called the Axess graft, came from Hong Kong-based China Grand Pharmaceutical and Healthcare Holdings Ltd. (Grand Pharma). The deal focuses mainly on commercializing Axess, but also involves other new products in the field of hemodialysis developed as part of the Xeltis technology platform. The commitment from Grand Pharma includes equity investment and product licensing, representing Xeltis’ first commercial deal and its first funding from an Asian concern.

Endometriosis affects one in 10 women, but diagnosis of this fertility impairing, and often painful condition often takes a decade. A growing number of companies hope to put women with the condition on the path to treatment much sooner with new diagnostics and investors, investigators and regulators see bright opportunities in the field.

3T Biosciences Inc. raised $40 million in a series A funding round to take forward a platform for identifying novel T-cell receptors (TCR) and their targets, which is based on the work of scientific co-founder K. Christopher Garcia of Stanford University.